Clinical applications of nimesulide in pain, arthritic conditions and fever

Bianchi, Mauro; Ehrlich, George E.; Facchinetti, Fabio; Huskisson, E.C.; Jenoure, P.; Marca, A. La; Rainsford, K. D.

doi:10.1007/3-7643-7410-1_5

Cited by 8 publications

(18 citation statements)

References 130 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…microglia, astrocytes) and endothelial cells also contributes to the cycle of activation of dorsal horn cells. From Bianchi et al (2005); unpublished fi gure. …”

Section: A Nimesulide Reduces Serum Levels Of Mmp In Osteoarthritismentioning

confidence: 98%

“…A large number of experimental investigations in animal models and humans with arthritic and various pain states (Bianchi et al, 2005) have shown that nimesulide has anti-infl ammatory activity which is comparable on a dose for weight basis with that of conventional NSAIDs such as diclofenac and indomethacin and the COX-2 selective drug, rofecoxib. The effects of nimesulide, like that of other NSAIDs on COX-2 are among the mechanisms involved in the anti-infl ammatory actions of this drug.…”

Section: Cox-2 and Anti-infl Ammatory Activitymentioning

confidence: 99%

See 1 more Smart Citation

Current status of the therapeutic uses and actions of the preferential cyclo-oxygenase-2 NSAID, nimesulide

Rainsford

2006

Inflammopharmacol

View full text Add to dashboard Cite

This review summarizes the principal therapeutic responses to the preferential COX-2 NSAID, nimesulide, in treating musculo-skeletal joint symptoms and various acute and chronic pain conditions and the mode of action in relation to therapy in these states. In extensive studies in laboratory animal models and clinical trails in patients nimesulide has been found to have potent analgesic, anti-inflammatory and anti-pyretic activities. It is approved for use in over 50 countries worldwide (including those in the EU, South and Central America, China, India and some other South-East Asia) for the treatment of acute pain, the symptomatic treatment of painful osteoarthritis and primary dysmenorrhoea. Its mode of action in these states is related to the preferential inhibition of the production of cyclo-oxygenase-2 (COX-2) and other inflammatory mediators whose production is controlled by stimulation of cyclic-3 ,5'-adenosine monophosphate (cAMP); this means that nimesulide is a multi-factorial drug in controlling inflammation and pain. The adverse reaction profile of nimesulide is, in general, like that of other NSAIDs. It does, however, have relatively low occurrence of gastro-intestinal (GI) side effects which is related to its low propensity to inhibit the physiologically important COX-1 in the GI mucosa and important physicochemical properties (high pKa of 6.5 and lipophilicity) as well as inhibiting of mast cell derived histamine and acid secretion in the stomach. In contrast with the coxibs, nimesulide has not been found to have appreciable cardiovascular toxicity.

show abstract

“…microglia, astrocytes) and endothelial cells also contributes to the cycle of activation of dorsal horn cells. From Bianchi et al (2005); unpublished fi gure. …”

Section: A Nimesulide Reduces Serum Levels Of Mmp In Osteoarthritismentioning

confidence: 98%

Section: Cox-2 and Anti-infl Ammatory Activitymentioning

confidence: 99%

Current status of the therapeutic uses and actions of the preferential cyclo-oxygenase-2 NSAID, nimesulide

Rainsford

2006

Inflammopharmacol

View full text Add to dashboard Cite

show abstract

“…In these studies nimesulide has consistently shown relief of inflammatory pain significantly superior to placebo and at least equivalent, or in some cases even superior, to that of other NSAIDs 17,47 . Nimesulide is particularly indicated for the treatment of acute pain, where inflammation is the predominant component.…”

Section: Clinical Evidence In Patients With Different Types Of Acute mentioning

confidence: 92%

Acute pain: a multifaceted challenge – the role of nimesulide

Kress

Baltov

Basiński

et al. 2015

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

“…НМ было посвящено более 200 клинических испытаний, в которых участвовало более 90 тыс. пациентов с острыми и хроническими забо-леваниями, сопровождавшимися болевым синдромом [15]. В этих работах было показано, что НМ позволяет существенно уменьшать боль, не уступая при этом по эффективности ни одному из НПВП, как селективным, так и неселективным.…”

unclassified

“…В клинических испытаниях НМ получали более 1000 женщин с первичной дисменореей [15]. В этих работах было продемонстрировано выраженное анальгетическое действие НМ, который превосходил по эффективности плацебо и другие НПВП, включая дикло-фенак и напроксен.…”

unclassified

Possibilities to Use Non-Steroid Anti-Inlammatory Drugs in Clinical Practice: Focus on Nimesulide

Olyunin¹,

Nikishina²

2017

Med. sov.

View full text Add to dashboard Cite

С келетно-мышечная боль является одной из наи-более актуальных проблем современной меди-цины. Заболевания, сопровождающиеся хрони-ческими болями, широко распространены в популяции. Стойкие боли могут приводить к резкому ограничению функциональных возможностей пациента и способство-вать сокращению продолжительности его жизни [1]. Они являются ведущим проявлением целого ряда болезней и обусловливают необходимость проведения длительной анальгетической терапии.На сегодняшний день НПВП являются основным ком-понентом фармакотерапии хронической ревматической боли и относятся к наиболее часто назначаемым медика-ментам. Мишенью для НПВП служит циклооксигеназа (ЦОГ) -ключевой фермент синтеза простагландинов (ПГ), опосредующих развитие воспалительного процесса. Синтез ПГ запускается с участием фосфолипазы А2, кото-рая отщепляет арахидоновую кислоту от мембранных фосфолипидов. ЦОГ, которая существует в двух изофор-мах (ЦОГ1 и ЦОГ2), интегрирована в липидный слой мем- Its protection is carried out with the participation of PG, the synthesis of which is controlled primarily by COX1, to a lesser extent -by COX2, inducing an inflammatory process. Therefore, one of the most effective measures to prevent disorders of the gastrointestinal tract, was the development of drugs that selectively inhibit the activity of COX2. Such drugs include, in particular, nimesulide (NM Nimesin, Shreya Life Senses). In addition to synthesis of PG-mediated COX2, NM inhibits a number of other mechanisms involved in the development of the inflammatory process. The ability of the NM to act simultaneously on many parts of the inflammatory process allows successfully using it in various inflammation-associated disease. NM was covered in over 200 clinical trials that included more than 90 thousand patients with acute and chronic diseases accompanied by pain syndrome. These authors demonstrated that NM can significantly reduce pain, being not inferior by effectiveness than any of the NSAIDs both: selective and non-selective. At the same the sparing effect of NM on COX1 allows maintaining sufficient concentration of prostanoids, providing physiological protection of the mucosa and reducing the frequency of adverse reactions from the GIT.

show abstract

Clinical applications of nimesulide in pain, arthritic conditions and fever

Cited by 8 publications

References 130 publications

Current status of the therapeutic uses and actions of the preferential cyclo-oxygenase-2 NSAID, nimesulide

Current status of the therapeutic uses and actions of the preferential cyclo-oxygenase-2 NSAID, nimesulide

Acute pain: a multifaceted challenge – the role of nimesulide

Possibilities to Use Non-Steroid Anti-Inlammatory Drugs in Clinical Practice: Focus on Nimesulide

Contact Info

Product

Resources

About